Jefferies Global Healthcare Conference, London, November 17, 2026
Madrigal Pharmaceuticals management used a fireside chat at the Jefferies Healthcare Conference in London to address the most debated question around its outcomes program: why the company has narrowed the timing of its ongoing F4c study while also launching a second, larger one. CEO William Sibold and Chief Medical Officer David Soergel said the decision reflects confidence rather than a hedge. Sibold also said the company has seen no impact from Novo Nordisk's Wegovy on Rezdiffra's growth, despite five quarters of competing against it.
A Second F4c Trial Framed as Confidence, Not a Backup
Jefferies analyst Akash Tewari put the bear reading to management directly: the company had narrowed the timing of the ongoing F4c study, which he had expected to be a 2027 event, and then announced a further trial with more patients, which some could read as a lack of confidence in the powering of the current study. Sibold rejected that interpretation. "Confidence. First and best, we're not here to participate. We're here to win," he said, adding that a company needs to "continuously generate new data in order to continue to extend your leadership position."
Sibold said the new study would take in learnings from the outcomes trial, the open-label data and how the field has moved, so that Madrigal can "leapfrog the competition that is expected in, I don't know, sometime around 2030 plus." He pointed to a growing F4c population as part of the logic. When the company first reported in 2023, it counted 245,000 F4c patients, a figure that has since risen to 360,000. That is already larger than the 315,000 patients Madrigal targeted at launch, and Sibold said the company has talked about F4c as doubling the opportunity. Pressed on whether the second study is effectively a derisking move, Sibold framed it as "confidence in the brand" and said the insights should apply to Rezdiffra and to the broader portfolio.
Tewari asked whether confidence in the ongoing study remains high. Soergel answered simply, "Yes."
Late 2027 Timing Rests on Event Accrual in a 845-Patient Trial
Soergel explained that the MAESTRO-NASH OUTCOMES readout is event driven. Management had always said it needed to get further into the study to gain confidence in timing, and that point was reached last quarter, which allowed the company to move from a full-year 2027 window to late 2027. "If the event rate accelerates, then we would deliver earlier than late 2027. And if they slow down, it would be a little later," he said, adding that late 2027 is the best current estimate.
Tewari asked whether a pickup in events explained the narrowed guidance. Soergel declined to describe the trajectory. He did say that in a trial of 845 patients targeting roughly 10% of the number of events typical for a cardiovascular outcomes study, accrual is uneven. "You can go weeks without any events and then you can have 3 or 4 events happen in a week," he said, which is why the study had to progress before timing could be predicted more precisely.
How the Field Has Moved Since the Original F4c Design
Soergel said the original design, built four to five years ago by the clinical team, used VCTE, platelets, MRE and other markers that were then less established. Since then, risk stratification has become more refined. He cited the ANTICIPATE-NASH algorithm, which emerged and was validated over the past year and combines VCTE, platelets and BMI to estimate the risk of events within three years, replacing the more categorical Baveno criteria. He also pointed to refinements in ELF and to other emerging blood-based biomarkers, as well as to regulatory acceptance of endpoints such as varices in F4.
Soergel said the current study is "well enriched, but we can do better." Improvements could come from excluding earlier-stage patients who do not contribute events, and from avoiding patients so advanced that they might have an event the day after randomization, leaving no opportunity for therapy to change their course. He called the target the "sweet spot" of patients far enough along but not too far. Madrigal has also run blinded analyses of MAESTRO-NASH OUTCOMES to identify patient characteristics that predict events, which Soergel said gives more confidence in designing the next trial. He said the company will not discuss those analyses because the data are "in the lockbox."...